Clincosm LogoSign in Get a demo

Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder

Sponsor
Johns Hopkins University (Other)
Overall Status
Completed
CT.gov ID
NCT04226352
Collaborator
(none)
5
Enrollment
1
Location
3
Arms
20.8
Actual Duration (Months)
0.2
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is an open-label dosing pilot study of 15 patients aged 18-50 years of age with diagnoses of Major Depressive Disorder (MDD) randomized to 1 of 3 treatment arms.

The study will consist of a screening evaluation performed within the course of 2 weeks, followed by an active treatment period of 28 days where treatment arm 1 will take a supervised dose of 300mg DXM every 14 days for 28 days, treatment arm 2 will take the FDA approved maximum daily ingestion for cough (60mg DXM) daily for 28 days, and treatment arm 3 will take 1 supervised dose of 300mg DXM and 60mg for the remaining 28 days. After the active treatment period, subjects will be followed for 65 days with safety and psychiatric assessments at designated timepoints.

Condition or Disease Intervention/Treatment Phase
Phase 1/Phase 2

Study Design

Study Type:
Interventional
Actual Enrollment :
5 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
An Open-Label Tolerance Study of Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder
Actual Study Start Date :
Mar 15, 2020
Actual Primary Completion Date :
Dec 7, 2021
Actual Study Completion Date :
Dec 7, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Dose 1

60 mg DXM a day for 28 days

Drug: Dextromethorphan
Dextromethorphan will be administered and its tolerability evaluated.
Experimental: Dose 2

300 mg DXM every 2 weeks for 28 days.

Drug: Dextromethorphan
Dextromethorphan will be administered and its tolerability evaluated.
Experimental: Dose 3

300mg DXM once, with 60mg DXM daily afterwards

Drug: Dextromethorphan
Dextromethorphan will be administered and its tolerability evaluated.

Outcome Measures

Primary Outcome Measures

  1. Time to All-Cause Discontinuation of Dextromethorphan [Up to 90 days]

    This will be measured in days from the first administration of the drug until discontinuation.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Subject must be a man or woman, 18 to 50 years, inclusive

  • Subject must meet Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-V) criteria for MDD without psychotic features based on clinician assessment.

  • Subjects must have undergone 3 or fewer antidepressant trials

  • Subjects must have moderate to severe depression as determined by a screening Montgomery-Åsberg Depression Rating Scale (MADRS) score of 20 or greater

Exclusion Criteria:

  • Subject has a current diagnosis of Bipolar Affective Spectrum Disorder, obsessive compulsive disorder, or a DSM-V personality disorder

  • Subject has had an incomplete response to more than 3 antidepressant trials

  • Subject cannot tolerate 60mg DXM as determined by study physician

  • Subject meets DSM-5 severity criteria for moderate or severe substance or alcohol use disorder within 6 months of screening, excluding caffeine or nicotine

  • Subject has a current clinical diagnosis of autism, dementia, or intellectual disability

  • Subject has history of psychosis not attributable to organic/metabolic causes

  • Subject has a history of serotonin syndrome or sensitivity

  • Subject has taken venlafaxine or a monoamine oxidase inhibitor (MAOI) within 4 weeks prior to screening

  • Subject is actively taking an opiate antagonist for any indication

  • Subject is taking a higher-than-recommended dosage of serotonergic antidepressant [including but not limited to selective serotonin reuptake inhibitor (SSRI), serotonin-norepinephrine reuptake inhibitor (SNRI), serotonin partial agonist/reuptake inhibitor (SPARI), serotonin antagonist and reuptake inhibitor (SARI) within 4 weeks prior to screening

  • Subject is actively suicidal

  • Subject has participated in another clinical drug trial within 6 months prior to screening

  • Subject has a history or current signs of liver or renal insufficiency

  • Subject has a clinically significant condition of any organ system that might adversely impact subject health upon consumption of DXM

  • Subject has previous history of intolerance to ketamine or its enantiomers

  • Subject has previous history of incomplete antidepressant response to ketamine or its enantiomers

  • Subject is currently using DXM for any indication

Contacts and Locations

Locations

Site City State Country Postal Code
1 Johns Hopkins Department of Psychiatry Baltimore Maryland United States 21287

Sponsors and Collaborators

  • Johns Hopkins University

Investigators

  • Principal Investigator: Anupama Kumar, Johns Hopkins University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT04226352
Other Study ID Numbers:
  • IRB00192193
First Posted:
Jan 13, 2020
Last Update Posted:
Jan 24, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
Yes
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Depressive Disorder, Treatment-Resistant
Dextromethorphan

Study Results

No Results Posted as of Jan 24, 2022